Vascular Medicine News

Editor’s Note: This is part 1 of a two-part Healio Exclusive series on renal denervation for hypertension control.

Despite larger declines in STEMI and non-STEMI events from 2011 to 2018, women received proportionately fewer revascularization procedures and had a higher STEMI mortality rate vs. men, researchers reported.

Healio has compiled a list of the top headlines in cardiology from February 2024.

Boston Scientific announced the FDA approval of its drug-coated balloon indicated for the treatment of coronary in-stent restenosis in patients with coronary artery disease.

Black patients and those with interstitial fibrosis or advanced-stage disease had a higher risk for developing clinically detectable postoperative venous thromboembolism after pulmonary resection for lung cancer, study results showed.

Six biomarkers were associated with baseline and treatment-associated changes in arterial inflammation in patients with rheumatoid arthritis and could be used to predict CVD risk in that population, researchers reported.

U.S. adults who reported cannabis use were at higher risk for coronary heart disease, MI and stroke compared with nonusers, with the risks persisting for cannabis users who reported never smoking tobacco, data show.

Pharmacists are one of the most accessible health care providers and singularly well positioned to lead efforts in integrating pharmacogenomics testing to improve medication-related outcomes.

Data show one in three patients in Denmark with obesity, no diabetes and a first-time MI met eligibility criteria for the SELECT CV outcomes trial, and that one major CV event can be prevented for every 49 people who receive semaglutide.

In a real-world cohort, people with the highest levels of lipoprotein(a) had the greatest risk for long-term major adverse CV events, regardless of whether they had atherosclerotic CVD at baseline, researchers reported.